BCR and acute lymphoblastic leukemia: Subsequently, we analyzed the impact of the BCL2 inhibition on BCR-ABL1 downstream targets STAT5 in Ph+ B-ALL cells using CRKL as control for BCR-ABL1 kinase suppression [24] (Figure 6).